Marker and detection product for gastric cancer peritoneal metastasis and application of marker and detection product

By detecting circPTBP3 in plasma of gastric cancer patients as a marker, using exosomes and reverse transcription polymerase chain reaction technology, the sensitivity and practicality of existing gastric cancer diagnosis methods are solved, achieving high accuracy and convenience Diagnosis and prognosis evaluation.

CN118995933APending Publication Date: 2024-11-22THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411294420.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-14
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing diagnostic methods for peritoneal metastasis of gastric cancer lack sensitivity and practicality, especially the invasiveness of abdominal cavity exploration and difficulty in detecting micrometastasis. The diagnostic effect of CT imaging is poor, resulting in increased difficulty in treating gastric cancer.

Method used

By detecting circular RNA (circPTBP3) in exosomes in the patient's plasma as a marker, a quantitative reverse transcription polymerase chain reaction is used to form cDNA samples, achieving sensitivity and accurate diagnosis of peritoneal metastasis of gastric cancer.

Benefits of technology

This method does not require invasive operation and is easy to operate. It can significantly improve the diagnostic accuracy and practicality of gastric cancer peritoneal metastasis, reduce detection errors, provide uniform standards, and improve the convenience and accuracy of diagnosis and prognosis evaluation of gastric cancer peritoneal metastasis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995933A_ABST
    Figure CN118995933A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, in particular to a marker for gastric cancer peritoneal metastasis, a detection product and application of the marker and the detection product. The content of circPTBP3 in the plasma exosome of the to-be-detected person is detected through the detection product, whether the to-be-detected person has gastric cancer peritoneal metastasis or not is judged, or the prognosis condition of gastric cancer peritoneal metastasis of the to-be-detected person is evaluated, operation is convenient, high accuracy is achieved, and high practicability is achieved clinically.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a marker for gastric cancer peritoneal metastasis, a detection product and application thereof. Background Art

[0002] Gastric cancer is a global health problem, and peritoneal metastasis is one of the most common metastatic patterns of gastric cancer. Nearly one-third of gastric cancer patients have already developed peritoneal metastasis at the time of diagnosis, and it accounts for more than half of distant metastases. Peritoneal metastasis of gastric cancer is highly hidden and complex, with a very poor prognosis and easy recurrence, which increases the difficulty of gastric cancer treatment.

[0003] Currently, peritoneal metastasis of gastric cancer is usually diagnosed through abdominal exploration or computed tomography (CT). However, CT imaging lacks diagnostic sensitivity, and abdominal exploration requires invasive procedures, which increases the risk of metastasis and makes it difficult to detect peritoneal micrometastases. Therefore, the current methods for diagnosing peritoneal metastasis of gastric cancer are of low practicality. Summary of the invention

[0004] The purpose of the present invention is to provide a marker for gastric cancer peritoneal metastasis with high practicality, a detection product and application thereof.

[0005] In order to achieve the above object, the present invention provides the following technical solutions:

[0006] A marker for gastric cancer peritoneal metastasis, wherein the marker is circPTBP3 and the biological sample is plasma of a person to be tested.

[0007] Optionally, the detection sample is exosomes in the biological sample.

[0008] In a second aspect, the present invention further provides a detection product for the above-mentioned marker, comprising:

[0009] A nucleic acid extraction reagent set, used to extract RNA in exosomes in the plasma to form a quantitative sample;

[0010] The quantitative reagent set is used for quantitative detection of the quantitative sample.

[0011] Optionally, the quantitative reagent set is used to detect and quantify the quantitative sample by quantitative reverse transcription polymerase chain reaction.

[0012] Optionally, the quantitative reagent set includes circPTBP3 primers for reverse transcription of the quantitative sample to form a cDNA sample.

[0013] Optionally, the forward primer sequence of the circPTBP3 primer is 5'

[0014] -TCTGAGGAAGCTGCCGTTAC-3', and the reverse primer sequence of the circPTBP3 primer is 5'-CATCAGATCCCCGAGCTTGA-3'.

[0015] Optionally, the detection product further comprises an exosome extraction reagent set for extracting the exosomes in the plasma.

[0016] In a third aspect, the present invention also provides the use of the above-mentioned detection product in the diagnosis of peritoneal metastasis of gastric cancer.

[0017] Alternatively, the expression level of circPTBP3 in plasma exosomes of patients with gastric cancer peritoneal metastasis was significantly increased.

[0018] In a fourth aspect, the present invention also provides the use of the above-mentioned detection product in evaluating the prognosis of peritoneal metastasis of gastric cancer.

[0019] According to the first aspect of the present invention, by detecting the expression level of circPTBP3 in the plasma of the biological sample, that is, the person to be tested, it is judged whether the person to be tested has peritoneal metastasis of gastric cancer. Sampling only requires minimally invasive blood sampling, does not involve invasive operations, is easy to operate and will not cause the disease to worsen. Circular RNA (circRNA) is a special type of non-coding RNA with a characteristic single-stranded covalent closed loop structure. With the help of structural specificity, it is not easily degraded by RNA exonucleases and presents higher stability. In addition, circRNA has the characteristics of rich content, stable structure, spatiotemporal specificity and tissue cell specificity. It is detected in a variety of body fluids such as saliva, blood, and urine. Selecting circRNA as a marker for judging peritoneal metastasis of gastric cancer has high sensitivity and helps to improve practicality.

[0020] Furthermore, exosomes can be detected in a variety of body fluids and can carry a variety of signal molecules, such as proteins, DNA, circRNA, long non-coding RNA (lncRNA), microRNA (miRNA), messenger RNA (mRNA), etc., to mediate cell communication. The contents of exosomes secreted by tumor cells play an important role in indicating disease progression. Based on the membrane-encapsulated structure of exosomes, it helps to improve the detection rate of circRNA, so exosome detection has high accuracy and sensitivity. Detecting the expression of markers carried in exosomes helps to improve the accuracy of detection.

[0021] According to the second aspect of the present invention, the total RNA in the plasma exosomes of the human to be tested is extracted by the detection product and the expression level of the marker circPTBP3 is detected therein, which helps to reduce the detection error caused by different detection reagents and methods and improve the accuracy of the detection.

[0022] Furthermore, the marker circPTBP3 was detected and quantified by quantitative reverse transcription polymerase chain reaction, which has high accuracy, simple operation, low equipment requirements, and high practicality.

[0023] Furthermore, circPTBP3 in exosomes is reverse transcribed by specific circPTBP3 primers to form cDNA to be detected. Since circPTBP3 primers have high specificity, they help to exclude the influence of PTPB3 linear transcripts, thereby making the content determination of marker circPTBP3 more accurate.

[0024] According to the third aspect of the present invention, the detection of the marker circPTBP3 by the detection product helps to form a uniform standard for judging the peritoneal metastasis of gastric cancer, thereby improving the accuracy of diagnosis. By providing an integrated detection product, it helps to improve the convenience of marker content detection and also helps to improve the convenience of diagnosis of peritoneal metastasis of gastric cancer.

[0025] According to the fourth aspect of the present invention, by detecting the content of the marker circPTBP3 in the detection product, it is helpful to form a unified standard and operating procedure for evaluating the prognosis of gastric cancer peritoneal metastasis, thereby improving convenience and accuracy.

[0026] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention and implement it according to the contents of the specification, the following is a detailed description of the preferred embodiments of the present invention in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is an image of exosomes observed under an electron microscope in the present invention;

[0028] Figure 2 This is a statistical diagram of the particle size distribution of exosomes in the present invention;

[0029] Figure 3 This is a graph showing the results of protein immunoblotting assay for detecting protein expression in the present invention;

[0030] Figure 4 It is a volcano plot of differential analysis of circRNA sequenced in mesothelial cells treated with exosomes in the present invention;

[0031] Figure 5 This is the volcano plot of the differential analysis of circRNA in gastric cancer tissues relative to paracancerous tissues in the present invention;

[0032] Figure 6 It is a Venn diagram of the RNA sequencing dataset, GSE174237 dataset and plasma exosome dataset in the present invention;

[0033] Figure 7 Schematic diagram of the source locus and looping of circPTBP3;

[0034] Figure 8 The electrophoresis diagram of the products after reverse transcription PCR with various primers in the present invention;

[0035] Fig. 9 It is a first-generation gene sequencing diagram of the products after reverse transcription PCR using multiple primers in the present invention;

[0036] Fig.10 This is a comparison chart of circPTBP3 expression levels in plasma exosomes of samples from different groups in the present invention;

[0037] Fig.11 is the receiver operating characteristic curve of the expression level of circPTBP3 in plasma exosomes for diagnosing gastric cancer and peritoneal metastasis in the present invention;

[0038] Fig.12 This is the KM curve of the present invention for evaluating the prognosis of gastric cancer patients using the expression level of circPTBP3 in plasma exosomes. DETAILED DESCRIPTION

[0039] The technical solution of the present invention will be described clearly and completely below in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0040] In the description of the present invention, it should be noted that the terms "center", "upper", "lower", "left", "right", "vertical", "horizontal", "inner", "outer", etc., indicating the orientation or positional relationship, are based on the orientation or positional relationship shown in the drawings, and are only for the convenience of describing the present invention and simplifying the description, rather than indicating or implying that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as limiting the present invention. In addition, the terms "first", "second", and "third" are used for descriptive purposes only, and cannot be understood as indicating or implying relative importance.

[0041] In the description of the present invention, it should be noted that, unless otherwise clearly specified and limited, the terms "installed", "connected", and "connected" should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection, or it can be indirectly connected through an intermediate medium, or it can be the internal communication of two components. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.

[0042] In addition, the technical features involved in the different embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.

[0043] Gastric cancer peritoneal metastasis is a common metastasis pattern of gastric cancer. This metastasis pattern is highly hidden and difficult to observe intuitively and accurately through imaging methods. Currently, abdominal exploration is often used for diagnosis. However, abdominal exploration is likely to increase the risk of metastasis, so it is necessary to find a method to diagnose gastric cancer peritoneal metastasis through markers in biological samples.

[0044] According to the prior art, it is known that human gastric cancer cell MGC803 has a tendency to metastasize to the peritoneum. The inventors found that the exosomes secreted by human gastric cancer cell MGC803 would act on human medullary cells, ultimately leading to peritoneal metastasis of gastric cancer. Based on this, the inventors screened the markers of exosomes produced by human gastric cancer cell MGC803 by genetic methods. Since the circular structure of circRNA has a high structural stability and is not easy to denature during the transfer of exosomes in the blood, circRNA was used as the research object of this screening.

[0045] Human gastric cancer cells MGC803 were cultured. When the cell confluence density reached more than 70%, the cells were washed 2 to 3 times with phosphate buffered saline (PBS) to remove residual bovine serum, and serum culture medium without exosomes was added and cultured for 24 hours.

[0046] The supernatant was centrifuged at 250g for 10 minutes, then at 1500g for 15 minutes at 4°C, and then the supernatant was centrifuged at 10000g for 30 minutes at 4°C, and then the supernatant was centrifuged again at 14000g for 30 minutes at 4°C. The supernatant was transferred to an ultracentrifuge tube, and then equilibrated with PBS and centrifuged at 110000g for 120 minutes at 4°C in an ultracentrifuge. The supernatant was discarded and the precipitate was resuspended with PBS, and then centrifuged again at 110000g for 60 minutes at 4°C in an ultracentrifuge. After discarding the supernatant, the exosomes secreted from MGC803 were obtained.

[0047] The exosomes were resuspended in PBS and dropped onto a sample-carrying copper mesh with a pore size of 2 nm. After standing at room temperature for 2 minutes, the liquid was absorbed from the side of the filter mesh with filter paper, and negatively stained with 3% phosphotungstic acid solution at room temperature for 5 minutes. After the negative staining liquid was absorbed by the filter paper, it was dried at room temperature, and the exosomes were observed and photographed by transmission electron microscopy. The images are shown in Figure 1 , it can be seen that the exosome structure remains intact.

[0048] The exosomes were appropriately diluted to 1.0 × 10 8 ~2.0×10 9800 μl of diluted exosome sample was extracted and analyzed by nanoparticle size analyzer to record the particle size distribution of exosomes. The data analysis results are shown in Figure 2 , it can be seen that the particle size distribution of exosomes is relatively uniform.

[0049] The precipitate produced during low-speed centrifugation was washed to obtain MGC803 to form a cell group sample, and the separated exosomes were used to form an exosome group sample. The expression levels of specific protein markers CD9, CD63, TSG101 and negative marker GAPDH on the exosome membrane were detected by protein immunoblotting. The test results are shown in Figure 3 It can be seen that in the Cell group samples, CD9 and CD63 were almost not expressed, the expression level of TSG101 was poor, and the expression level of GAPDH was good. In contrast, in the Exo group samples, the expression levels of CD9, CD63 and TSG101 were good, while the expression level of GAPDH was poor. This indicates that the Exo group samples are exosomes.

[0050] Mesothelial cells were treated with the above exosomes, and RNA was extracted from untreated and treated mesothelial cells. Whole transcriptome sequencing was performed by Shanghai Ouyi Company, and the sequencing data was analyzed for differences with the sequencing data in the public database. Figure 4 , the RNA in the untreated mesothelial cells and the treated mesothelial cells was analyzed by volcano plot, and an RNA sequencing dataset containing 277 circRNAs whose expression was upregulated after exosome treatment was obtained, including the RNA contained in the above exosomes and the RNA whose expression was upregulated in mesothelial cells under the action of the above exosomes. Figure 5 , circRNA datasets of gastric cancer tissues and para-cancer tissues were selected from the existing GEO database and compared through volcano plots. The GSE174237 dataset contains 64 circRNAs whose expression levels are upregulated in gastric cancer tissues relative to para-cancer tissues. The circRNAs in the GSE174237 dataset are all circRNAs whose expression levels are upregulated after gastric tissues become cancerous, that is, these circRNAs are functionally related to gastric cancer, and their expression levels are upregulated in exosomes secreted after cancer. Please refer to Figure 6 , a plasma exosome dataset that was significantly upregulated in the plasma exosomes of gastric cancer patients was obtained from existing literature, and compared with the RNA sequencing dataset and the GSE174237 dataset to obtain the candidate circRNA of the intersection, namely circPTBP3. It was speculated that circPTBP3 in plasma exosomes could be used as a marker for peritoneal metastasis of gastric cancer.

[0051] A validation experiment was conducted using circPTBP3 in plasma exosomes as a marker for peritoneal metastasis of gastric cancer. For details, please refer to the following examples.

[0052] Embodiment 1:

[0053] In a preferred embodiment of the present application, 110 clinical biological samples and 30 healthy biological samples provided by healthy volunteers were selected for reliability experiments, and the content of exosome markers in the biological samples was detected by the detection product.

[0054] The clinical biological samples used in this embodiment were from the First Affiliated Hospital of Soochow University. Among the patients with samples collected, 80 were without peritoneal metastasis and 30 were with peritoneal metastasis. Clinical biological samples were taken from the peripheral blood of patients before surgery, and none of the patients received chemotherapy. The healthy biological samples provided by healthy volunteers were taken from the peripheral blood of volunteers. All plasma samples were separated and frozen in a -80°C refrigerator, and all plasma samples were collected with the informed consent of the patients or volunteers and approved by the hospital ethics committee. The clinical data of all participants are shown in Table 1.

[0055] Table 1:

[0056]

[0057]

[0058] The detection products include exosome extraction reagent set, nucleic acid extraction reagent set and quantitative reagent set. Please refer to the following description for details.

[0059] Exosome extraction reagent sets were used to extract exosomes from clinical biological samples and healthy biological samples, respectively. In this embodiment, the exosome extraction reagent set includes the exoEasy kit, and the following filter element, membrane affinity centrifugal column, collection tube and buffer are all from the exoEasy kit.

[0060] Use a 0.22 micron filter to filter impurities in the plasma, and mix the filtered plasma and binding (XBP) buffer at a volume ratio of 1:1. Transfer the mixture to a membrane affinity centrifuge column, centrifuge at 500g for 1 minute, add 10ml of wash (XWP) buffer, and centrifuge at 5000g for 5 minutes. Transfer the membrane affinity centrifuge column to a new collection tube, add 400μl of elution (XE) buffer, incubate for 1 minute, centrifuge at 500g for 1 minute, collect the eluate and transfer it back to the membrane affinity centrifuge column, centrifuge again at 5000g for 5 minutes, and store the eluate in a -80℃ refrigerator.

[0061] The RNA in the exosomes of clinical biological samples and healthy biological samples was extracted using a nucleic acid extraction reagent set. In this embodiment, the nucleic acid extraction reagent set is an RNA extraction kit, and the following Trizol, chloroform, isopropanol, 75% ethanol and diethyl pyrocarbonate water are all from the RNA extraction kit.

[0062] The above eluate was transferred to an ultracentrifuge tube, balanced with PBS, and centrifuged at 110,000 g for 120 minutes at 4°C in an ultracentrifuge. The supernatant was discarded and the precipitate was resuspended with PBS. The supernatant was discarded to obtain plasma exosomes. 1 ml of Trizol was added to the plasma exosomes, pipetted several times and transferred to a centrifuge tube; the lysate was placed at room temperature for 5 minutes to completely separate the nucleic acid-protein complex, and 200 μl of chloroform was added, the tube lid was tightly closed, and the tube was shaken vigorously for 15 seconds and placed at room temperature for 3 minutes; the tube was centrifuged at 12,000 g for 15 minutes at 4°C, the upper aqueous phase containing total RNA was aspirated and transferred to a new centrifuge tube, 500 μl of isopropanol was added, and the mixture was mixed by inversion several times, and placed at room temperature for 10 minutes. Centrifuge at 12000g for 10 minutes at 4°C, discard the supernatant, and a gelatinous RNA precipitate can be seen. Add 1 ml of 75% ethanol, invert several times to mix and wash the precipitate, and centrifuge again at 12000g for 5 minutes at 4°C, discard the supernatant, and invert at room temperature for 10 minutes to dry. Add 20 to 50 microliters of diethyl pyrocarbonate water until the RNA precipitate is completely dissolved, and detect the RNA purity and concentration under an ultra-micro spectrophotometer (NanoDrop). After the experiment, the remaining samples are stored in a -80°C refrigerator.

[0063] The quantitative reagent set was used to quantify circPTBP3 in exosome RNA extracted from clinical biological samples and healthy biological samples. In this example, quantitative reverse transcription polymerase chain reaction was used for detection, and the quantitative reagent set included circPTBP3 primers, reverse transcription kit, 2X SuperMix, internal reference dye ROXII and nuclease-free water.

[0064] See also Figure 7 circPTBP3 is named hsa_circ_0003500 in the circBase database and is formed by reverse splicing of exons 3, 4, and 5 of the PTBP3 locus on chromosome 9. In this example, circPTBP3 primers were designed based on the reverse splicing site to make it have strong specificity. The specificity verification includes:

[0065] After RNA was treated with exoribonuclease (RnaseR), reverse transcription PCR was performed using circPTBP3 primers, linear PTBP3 primers, and GAPDH primers at a concentration of 10 μmol / Ll. CircPTBP3 primers, linear PTBP3 primers, and GAPDH primers all have forward and reverse sequences, and the specific sequences are shown in Table 2 below.

[0066] Table 2

[0067]

[0068]

[0069] See also Figure 8 By detecting the circular structure of circRNA by electrophoresis, it can be seen that the amplified product has a circular structure with uniform charge distribution. Fig. 9 The amplified products were sequenced by GENEWIZ, and the circRNA sequences were compared and the reverse splicing sites of circRNA were analyzed. It can be seen that the product amplified by the designed circPTBP3 primers is the target circRNA, which proves that the designed circPTBP3 primers have good specificity.

[0070] The above-mentioned circPTBP3 primers and reverse transcription kit were used to perform reverse transcription PCR on the exosome RNA extracted from clinical biological samples and healthy biological samples. The following PCR reaction tubes and 5XAll-in-one Mix were all from the reverse transcription kit. Since exosomes lack internal reference, the plasma exosome protein concentration of each sample was used for quantification, and diluted to the same volume after RNA extraction, and then the same volume of RNA was taken to reverse into cDNA.

[0071] The method of reverse transcription PCR includes: adding 1 μl of RNA, 0.8 μl of forward circPTBP3 primer, 0.8 μl of reverse circPTBP3 primer, and 4 μl of 5XAll-in-one Mix to the PCR reaction tube, wherein the concentration of the forward circPTBP3 primer and the reverse circPTBP3 primer are both 10 μmol / L, and the system is supplemented to 20 μl with nuclease-free water and mixed, and placed in a common PCR instrument for centrifugation. The reaction procedure is: 25°C for 10 minutes, 42°C for 15 minutes, 85°C for 5 minutes, and 4°C for a long time. The cDNA obtained after the reaction is used for quantitative polymerase chain reaction (qPCR), and the remaining cDNA is stored in a -80°C refrigerator.

[0072] The cDNA obtained by reverse transcription was quantified by qPCR.

[0073] A 20 μl reaction system was used. 10 μl of 2XSuperMix, 2 μl of cDNA, 0.8 μl of forward circPTBP3 primer, 0.8 μl of reverse circPTBP3 primer, 0.4 μl of ROXII and 6 μl of nuclease-free water were added to each well of a 96-well PCR reaction plate. The reaction system was prepared and centrifuged. The reaction system was then placed in an ABI ViiA 7 fluorescence quantitative PCR instrument. The reaction procedure is shown in Table 3 below.

[0074] Table 3:

[0075]

[0076]

[0077] After the reaction, 30 healthy biological samples were used as the normal group, 80 clinical biological samples without peritoneal metastasis were used as the gastric cancer patient group without peritoneal metastasis, and 30 clinical biological samples with peritoneal metastasis were used as the gastric cancer patient group with peritoneal metastasis.

[0078] Based on the average Ct value of the healthy biological sample group, the expression level of each sample compared with the baseline was calculated. -ΔCt value.

[0079] Statistical analysis was performed using SPSS 26.0 software (IBM, USA).

[0080] The differences between the two groups were analyzed using Student's t test, and all statistical data were expressed as mean ± SD. Fig.10 , ns in the figure means no statistical difference between the groups, * means p<0.05, ** means p<0.01, and *** means p<0.001. As can be seen from the figure, there is no significant difference in the expression level of plasma exosome circPTBP3 between gastric cancer patients and healthy people, while the expression level of plasma exosome circPTBP3 in patients with peritoneal metastasis of gastric cancer is significantly higher than that in patients with gastric cancer without peritoneal metastasis (p<0.001).

[0081] The receiver operating characteristic (ROC) curve is used to demonstrate the diagnostic efficacy, and the area under the curve (AUC value) is used to quantitatively evaluate the diagnostic efficacy. Fig.11 The AUC value of the ROC curve for distinguishing gastric cancer patients from healthy subjects using plasma exosomal circPTBP3 expression levels was 0.595 (p=0.124), while the AUC value of the ROC curve for distinguishing gastric cancer patients with peritoneal metastasis from those without peritoneal metastasis was 0.866 (p<0.001). This proves that the expression level of plasma exosomal circPTBP3 is difficult to distinguish gastric cancer patients from healthy subjects, but can distinguish whether gastric cancer patients have peritoneal metastasis. Fig.11The optimal cutoff value for distinguishing whether gastric cancer patients have peritoneal metastasis was 1.931, that is, when the expression level of circPTBP3 in the plasma exosomes of gastric cancer patients was higher than 1.931, gastric cancer patients were judged to have peritoneal metastasis. At this time, the sensitivity of the detection was 76.67%, and the specificity was 86.25%.

[0082] Combination Fig.10 and Fig.11 The results showed that circPTBP3 was significantly upregulated in tumor tissues and plasma exosomes of patients with peritoneal metastasis of gastric cancer, and the expression level of plasma exosome circPTBP3 had a high diagnostic value.

[0083] KM survival analysis was used to evaluate patient prognosis. When p value < 0.05, it means that the difference between components is statistically significant. Fig.12 Gastric cancer patients with high expression of plasma exosomal circPTBP3 had a worse prognosis than those with low expression, which was statistically significant (log-rank p < 0.001).

[0084] The univariate and multivariate COX proportional-hazards models were used to evaluate the effect of circPTBP3 expression levels in plasma exosomes on the prognosis of gastric cancer patients. The analysis results are shown in Table 4 below.

[0085] Table 4:

[0086]

[0087] In Table 4, when the p value is less than 0.05, * is marked after the value. As can be seen from the table, the hazard ratio of circPTBP3 expression is 1.763 (1.042-2.982) and the p value is 0.035. circPTBP3 expression and tumor differentiation can be used as independent risk factors for predicting the prognosis of gastric cancer patients.

[0088] The beneficial effect of the present invention is that the content of circPTBP3 in the plasma exosomes of the person to be tested is detected by the detection product, so as to judge whether the person to be tested has peritoneal metastasis of gastric cancer, or evaluate the prognosis of peritoneal metastasis of gastric cancer in the person to be tested. The operation is convenient and has high accuracy, and the method has high practicality in clinical practice.

[0089] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0090] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A marker for peritoneal metastasis of gastric cancer, characterized in that: The marker is circPTBP3, and the biological sample is plasma of the person to be tested.

2. The marker according to claim 1, characterized in that The detection sample is the exosomes in the biological sample.

3. A marker detection product as claimed in claim 1 or 2, characterized in that: include: A nucleic acid extraction reagent set, used to extract RNA in exosomes in the plasma to form a quantitative sample; The quantitative reagent set is used for quantitative detection of the quantitative sample.

4. The detection product according to claim 3, characterized in that: The quantitative reagent set is used to detect and quantify the quantitative sample through quantitative reverse transcription polymerase chain reaction.

5. The detection product according to claim 4, characterized in that: The quantitative reagent set includes circPTBP3 primers used for reverse transcription of the quantitative sample to form a cDNA sample.

6. The detection product according to claim 5, characterized in that: The forward primer sequence of the circPTBP3 primer is 5'-TCTGAGGAAGCTGCCGTTAC-3', and the reverse primer sequence of the circPTBP3 primer is 5'-CATCAGATCCCCGAGCTTGA-3'.

7. The detection product according to claim 3, characterized in that: Also included is an exosome extraction reagent set for extracting the exosomes in the plasma.

8. Use of the detection product according to any one of claims 2 to 7 in the diagnosis of peritoneal metastasis of gastric cancer.

9. The use according to claim 8, characterized in that The expression level of circPTBP3 in plasma exosomes of patients with gastric cancer peritoneal metastasis was significantly increased.

10. Use of the detection product according to any one of claims 2 to 7 in evaluating the prognosis of peritoneal metastasis of gastric cancer.

Citation Information

Cited By

  • Application of tRF-Arg-CCT-021 in gastric cancer peritoneal metastasis diagnosis

    CN121380336A